Relmada Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 125.75 million compared to USD 59.46 million a year ago. Basic loss per share from continuing operations was USD 7.16 compared to USD 3.81 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | +0.33% | +3.04% | -26.33% |
06-05 | Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target | MT |
05-08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.33% | 91.73M | |
+17.54% | 124B | |
+15.47% | 109B | |
-7.13% | 23.84B | |
+2.10% | 22.42B | |
-14.15% | 17.5B | |
-10.18% | 16.61B | |
-41.64% | 16.43B | |
+2.18% | 13.4B | |
+26.29% | 11.47B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021